

## Jason Breen

PARTNER

Mergers &  
Acquisitions  
*Los Angeles*

jbreen@wsgr.com  
323-210-2996



### FOCUS AREAS

Corporate  
Corporate Governance  
Corporate Life Sciences  
Emerging Companies and  
Venture Capital  
Life Sciences  
Mergers & Acquisitions

### EXPERIENCE

Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.

Prior to joining Wilson Sonsini, Jason was an equity partner in Goodwin Procter's Los Angeles office. He started his legal career in the New York office of Simpson Thacher & Bartlett LLP.

### CREDENTIALS

#### Education

- J.D., UCLA School of Law, 2007
- B.S., Applied Mathematics, Harvard University, 2002

#### Honors

- Recognized as "Corporate Attorney of the Year" by the *Los Angeles Business Journal* in 2019
- Recognized in the *Legal 500*

#### Admissions

- State Bar of California
- State Bar of New York

### MATTERS

#### Select Matters

##### *Mergers and Acquisitions*

- Represented Taiho, an R&D-driven specialty pharmaceutical company, in its acquisition of Araris
- Represented DispatchHealth, a leading provider of high-acuity, in-home medical care, in its acquisition of Medically Home
- Represented Vertos, a privately held company providing a minimally invasive solutions for treating chronic lower back pain, in its sale to Stryker
- Represented Replace, a programmable genomic integration (PGI) company, in its sale to Tome
- Represented DTx Pharma, a biotech company, in its sale to Novartis
- Represented XinThera, a biotech company, in its sale to Gilead
- Represented Amphastar Pharmaceuticals in its acquisition of Eli Lilly's low blood sugar drug BAQSIMI
- Represented Caption Health, an AI healthcare leader that creates clinical applications to aid in early disease detection, in its sale to GE HealthCare

- Represented Inscopix, a company focused on high performance scientific instruments and analytical and diagnostic solutions, in its sale to Bruker
- Represented Obsidio, a medical device company, in its sale to Boston Scientific
- Represented Novosteo, a clinical-stage biopharmaceutical company, in its sale to Cortexyme
- Represented PillPack, an online pharmacy, in its sale to Amazon\*
- Represented Repligen, a life sciences company focused on bioprocessing technology leadership, in numerous acquisitions including its acquisitions of C Technologies, Spectrum, ArteSYN, Non-Metallic Solutions, Engineered Molding Technology, and BioFlex Solutions\*
- Represented Olo, a company that develops digital ordering and delivery programs for restaurants, in its acquisition of Wisely\*
- Represented BlueRock Therapeutics, a biotechnology company focusing on developing stem cell therapies, in its sale to Bayer\*
- Represented TripleLift, an adtech company, in its sale to Vista\*
- Represented AppNexus, an adtech company, in its acquisition of Open AdStream, YieldEx, MediaGlu, and Realmedia Latin America and in its sale to AT&T\*
- Represented Virustream, a cloud management firm, in its sale to EMC\*
- Represented Promedior, a clinical-stage immunotherapy company, in its grant to Bristol-Myers Squibb of an exclusive right to acquire Promedior and its ultimate sale to Roche\*
- Represented EverTrue, a company that develops advancement software, in its combination with ThankView and investment by Rubicon Technology Partners\*
- Represented Exosome, a company that develops and sells diagnostics that test for exosomes, in its sale to Bio-Techne\*
- Represented Aporeto, a machine identity-based microsegmentation company, in its sale to Palo Alto Networks\*
- OVH, a cloud service provider, in its acquisition of the vCloud Air business from VMware\*
- Represented Teva Pharmaceuticals, a pharmaceutical company, in its sale of its animal health business to Bayer Healthcare and its sale of four targeted oncology development programs to Ignyta\*
- Represented Interactions, a technology company, in its acquisition of the AT&T Watson technology program\*
- Represented Bomgar, a provider of enterprise remote support solutions, in TA Associates' majority investment in Bomgar\*
- Represented Numara Software, a provider of integrated IT management solutions, in its sale to BMC Software\*
- Represented Digital Lumens, a developer of industrial IoT solutions, in its sale to Osram\*

### ***Financings and Joint Ventures***

- Represented Borealis, a next-generation RNA medicines company, in its \$150 million Series A and strategic collaboration funding
- Represented BridgeBio, a biotechnology company that focuses on identifying and advancing transformative medicines for genetic diseases, in its joint venture with Maze Therapeutics and in its \$299 million financing\*
- Represented Century Therapeutics, a biotechnology company focusing on developing stem cell therapies for cancer, in its joint venture with Bayer\*
- Represented Versant Ventures, a venture capital firm focused on the healthcare sector, in its formation of BlueRock Therapeutics and joint venture with Bayer\*
- Represented CRISPR Therapeutics, a biotechnology company, in its formation of Casebia Therapeutics and joint venture with Bayer\*
- Represented Arvinas, a biotechnology company, in its joint venture with Bayer (Oerth Bio) focused on developing new agricultural products\*
- Represented Ginkgo Bioworks, a biotechnology company, in its joint venture with Bayer (Joyn Bio) focused on the plant microbiome\*
- Represented MyoKardia, a company developing precision therapies for genetic heart disease, in its \$46 million financing\*
- Represented Phreesia, a healthcare point-of-service platform, in its \$30 million financing led by LLR Partners\*
- Represented Global Blood Therapeutics, a biopharmaceutical company developing therapeutics for the treatment of severe blood disorders, in its \$48 million financing\*

### ***Initial Public Offerings***

- Represented BridgeBio, a biotechnology company that focuses on identifying and advancing transformative medicines for genetic diseases, in its initial public offering\*
- Represented MyoKardia, a company developing precision therapies for genetic heart disease, in its initial public offering\*

*\* Denotes experience at another firm prior to joining Wilson Sonsini in 2022.*

## INSIGHTS

---

### Select Publications

- Co-author, “How to Navigate the Decision of Exercising Drag-Along Rights During an M&A Process,” *Deal Lawyers*, September-October 2022